{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:20:02Z","timestamp":1777911602429,"version":"3.51.4"},"reference-count":41,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T00:00:00Z","timestamp":1450915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Knowledge of possible cardiovascular risks from Parkinson's disease (\n                      <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\n                      ) medications is critical to informing safe and effective treatment decisions. The objective of our study was to determine whether\n                      <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\n                      patients treated with nonergot dopamine agonists (\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      s) are at increased risk of adverse cardiovascular or cerebrovascular outcomes, relative to\n                      <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\n                      patients receiving other treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Matched case\u2010control studies were conducted within a cohort of 14,122 inpatients receiving treatment for\n                      <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\n                      who were identified in the Cerner Health Facts database. Primary outcomes were associations between nonergot\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      use and diagnosis of adverse cardiovascular events (acute myocardial infarction, heart failure [\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      ], hypotension, and valvulopathy). Secondary outcomes included associations between nonergot\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      use and diagnosis of adverse cerebrovascular events (cerebrovascular accident and ischemic stroke) and odds of significant exposure\u2010outcome relationships by patient factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      was the only adverse event that demonstrated a significant association with nonergot\n                      <jats:styled-content style=\"fixed-case\">DA<\/jats:styled-content>\n                      use. Individuals treated with pramipexole were more likely to be diagnosed with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      , relative to no use (adjusted odds ratio [\n                      <jats:styled-content style=\"fixed-case\">AOR<\/jats:styled-content>\n                      ]: 1.28; 95% confidence interval [\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      ]: 1.07\u20131.53). The association between pramipexole and\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      was greater among individuals treated with pramipexole monotherapy (relative to levodopa monotherapy) (\n                      <jats:styled-content style=\"fixed-case\">AOR<\/jats:styled-content>\n                      , 1.50; 95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      : 1.09\u20132.06). Compared to nonusers, men and older individuals treated with pramipexole were more likely to be diagnosed with\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Results from our study suggest an association between pramipexole use and\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      . Findings warrant replication; however, individuals with\n                      <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>\n                      and independent risk factors for, or a history of,\n                      <jats:styled-content style=\"fixed-case\">HF<\/jats:styled-content>\n                      may benefit from limited use of this drug.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mdc3.12286","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T08:56:18Z","timestamp":1450947378000},"page":"257-267","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease"],"prefix":"10.1002","volume":"3","author":[{"given":"James A.G.","family":"Crispo","sequence":"first","affiliation":[{"name":"McLaughlin Center for Population Health Risk Assessment University of Ottawa Ottawa Ontario Canada"},{"name":"Fulbright Canada Student University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison W.","family":"Willis","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Biostatistics &amp; Epidemiology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan P.","family":"Thibault","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Biostatistics &amp; Epidemiology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannick","family":"Fortin","sequence":"additional","affiliation":[{"name":"McLaughlin Center for Population Health Risk Assessment University of Ottawa Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Emons","sequence":"additional","affiliation":[{"name":"Cerner Corporation Culver City California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise M.","family":"Bjerre","sequence":"additional","affiliation":[{"name":"Department of Family Medicine University of Ottawa Ottawa Ontario Canada"},{"name":"C.T. Lamont Primary Health Care Research Center Bruy\u00e8re Research Institute Ottawa Ontario Canada"},{"name":"School of Epidemiology, Public Health and Preventive Medicine University of Ottawa Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna E.","family":"Kohen","sequence":"additional","affiliation":[{"name":"School of Epidemiology, Public Health and Preventive Medicine University of Ottawa Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Perez\u2010Lloret","sequence":"additional","affiliation":[{"name":"Institute for Cardiology Research (ININCA) National Research Council (CONICET) Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Mattison","sequence":"additional","affiliation":[{"name":"McLaughlin Center for Population Health Risk Assessment University of Ottawa Ottawa Ontario Canada"},{"name":"Risk Sciences International Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Krewski","sequence":"additional","affiliation":[{"name":"McLaughlin Center for Population Health Risk Assessment University of Ottawa Ottawa Ontario Canada"},{"name":"Risk Sciences International Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,12,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2014.09.009"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000129842.49926.07"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4065\/77.12.1280"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15945-X"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054830"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0102-z"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.11.009"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2267"},{"key":"e_1_2_7_10_1","unstructured":"U.S. Food and Drug Administration.FDA drug safety communication: ongoing safety review of Parkinson's drug Mirapex (pramipexole) and possible risk of heart failure.2012. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm319779.htm. Accessed February 18 2015."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724040-00001"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.3.377"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21225"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20887"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70117-0"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1084-6"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.10.2307"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00555-6"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.22.1.189"},{"key":"e_1_2_7_20_1","unstructured":"BergstralhE TherneauT.Mayo Clinic: biomedical statistics and informatics\u2014locally written SAS macros.2015. Available at:http:\/\/www.mayo.edu\/research\/departments-divisions\/department-health-sciences-research\/division-biomedical-statistics-informatics\/software\/locally-written-sas-macros. Accessed February 19 2015."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg068"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000275491"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20764"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21878"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(01)00023-2"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.12.003"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.09.002"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3654"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.988137"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropsychologia.2006.03.030"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5262"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000341996"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/956353"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.7.634"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01108-1"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-015-0252-x"},{"issue":"4","key":"e_1_2_7_38_1","first-page":"6A","article-title":"The epidemiology of heart failure: the Framingham Study","volume":"22","author":"Ho KK","journal-title":"J Am Coll Cardiol"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90225-7"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000896"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.12.008"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1881-4"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmdc3.12286","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.12286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:20:47Z","timestamp":1762258847000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.12286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,24]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1002\/mdc3.12286"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.12286","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,24]]},"assertion":[{"value":"2015-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}